SCHEMBL17835877

SCHEMBL17835877

O[C@@H](CN1CCOCC1)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.71
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
GAA P10253 1/20 0.65
OPRM1 P35372 1/20 0.63
OPRD1 P41143 1/20 0.63
POLB P06746 1/20 0.61
IGF1R P08069 2/20 0.55
HSD17B10 Q99714 1/20 0.55
ATM Q13315 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610052 1.00 KDM4E (0.71) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL1460360 1.00 KDM4E (0.71) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL2796836 0.87 GAA (0.82) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL10746494 0.87 GAA (0.82) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL1460325 0.85 MEN1 (0.57) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL31419975 0.84 KDM4E (0.73) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL1205842 0.83 GAA (0.71) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL3082979 0.83 GAA (0.71) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL6979453 0.83 GAA (0.71) KDM4EKMT2AMEN1GAAOPRM1
SCHEMBL13343050 0.83 HTR1A (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2019-02-14 US disclosed
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2019-02-14 US disclosed
US-10130619-B2 Amido thiadiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-11-20 US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US disclosed
EP-3233847-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2017-10-25 EP disclosed
CN-107207489-A It is used as the acylamino- thiadiazoles derivative of nadph oxidase inhibitor 吉恩基奥泰克斯瑞士股份有限公司 2017-09-26 CN disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 WO disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 WO disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 EP disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX5, CYBB KDM4E 4240/4885KMT2A 3963/4885MEN1 4380/4885
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX5, CYBB KDM4E 4240/4885KMT2A 3963/4885MEN1 4380/4885
US-10130619-B2 Amido thiadiazole derivatives as NADPH oxidase inhibitors NOX1, NOX5, CYBB KDM4E 4240/4885KMT2A 3963/4885MEN1 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.